Dihexadecyl Methylamine
16724-61-1
0.99%
shanghai
JH
180kgs/TIN
Yes
2022-11-30
Fluorine containing fine chemicals Pharmaceutical
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceLiquidBasic Info
-
Product Name:
N-Hexadecyl-N-methyl-1-hexadecanamine
Other Name:1-Hexadecanamine,N-hexadecyl-N-methyl-;Dihexadecylamine,N-methyl-;N-Hexadecyl-N-methyl-1-hexadecanamine;Dihexadecylmethylamine;N,N-Dihexadecylmethylamine;Armeen M 2-16;Methyldipalmitylamine
CAS No.:16724-61-1
Molecular Formula:C33H69N
InChIKeys:InChIKey=KCMTVIZYKDBFFS-UHFFFAOYSA-N
Molecular Weight:479.9 g/mol
Exact Mass:479.91
EC Number:266-923-8|605-470-6
UNII:NI19TV232A
DSSTox ID:DTXSID7028304
Categories:
Characteristics-
PSA:
3.2 Ų
Melting Point:36-37 °C
Boiling Point:269-271 °C @ Press: 1 Torr
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Fluorine containing fine chemicals Pharmaceutical
-
Location:
ADDRESS: NO.2350,DU ZHUANG ROAD, MINGHANG DISTRICT, SHANGHAI, CHINA
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
30 days
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2009
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
- Hot Searches
- tartaric acid where to buy
- where to buy cerebrolysin peptide
- retatrutide 30mg for sale
- propylene pricing
- ammonia index price
- hydroxypropyl cellulose price
- where to buy enclomiphene citrate
- hdpe prices
- methyl tertiary butyl ether msds
- fipronil cockroach bait
- triz peptide
- caustic soda prices
